Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N06 PSYCHOANALEPTICS
N06D ANTI-DEMENTIA DRUGS
N06DX Other anti-dementia drugs
N06DX01 Memantine
D04905 Memantine hydrochloride (JAN/USP) <JP/US>
USP drug classification [BR:br08302]
Antidementia Agents
N-methyl-D-aspartate (NMDA) Receptor Antagonist
Memantine
D04905 Memantine hydrochloride (JAN/USP)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
11 Agents affecting central nervous system
119 Miscellaneous
1190 Miscellaneous
D04905 Memantine hydrochloride (JAN/USP)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01498 NMDA receptor antagonist
DG00986 Memantine
D04905 Memantine hydrochloride
DG01968 Antidementia agent
DG00986 Memantine
D04905 Memantine hydrochloride
Transporter substrate
DG02854 SLC22A2 substrate
DG00986 Memantine
D04905 Memantine hydrochloride
Drug classes [BR:br08332]
Neuropsychiatric agent
DG01968 Antidementia agent
D04905 Memantine hydrochloride
Target-based classification of drugs [BR:br08310]
Ion channels
Ligand-gated ion channels
Glutamate (ionotropic), NMDA
GRIN (NMDAR)
D04905 Memantine hydrochloride (JAN/USP) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D04905
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D04905
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D04905
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D04905
Drug metabolizing enzymes and transporters [br08309.html]
Drug transporters
D04905
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01498 NMDA receptor antagonist
DG00986 Memantine
DG01968 Antidementia agent
DG00986 Memantine
Transporter substrate
DG02854 SLC22A2 substrate
DG00986 Memantine